Royalty and licensing income |
6 Months Ended |
|---|---|
Jan. 31, 2016 | |
| Royalty And Licensing Income [Abstract] | |
| Royalty And Licensing Income [Text Block] |
Note 11 – Royalty and licensing income The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the six months ended January 31, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $0.9 million and $1.6 million respectively, which is included in the Life Sciences segment. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure of royalty and licensing income at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. No definition available.
|